P/E ratio for Halozyme Therapeutics (HALO)
P/E ratio as of April 2024 (TTM): 22.4
According to Halozyme Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.3966. At the end of 2022 the company had a P/E ratio of 38.4.
P/E ratio history for Halozyme Therapeutics from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 38.4 | 172.5% |
| 2021 | 14.1 | -68.29% |
| 2020 | 44.5 | -225.46% |
| 2019 | -35.5 | 33.31% |
| 2018 | -26.6 | -152.52% |
| 2017 | 50.7 | -515.25% |
| 2016 | -12.2 | -81.7% |
| 2015 | -66.7 | 279.89% |
| 2014 | -17.5 | -14.56% |
| 2013 | -20.5 | 49.95% |
| 2012 | -13.7 | -71.2% |
| 2011 | -47.6 | 236.21% |
| 2010 | -14.1 | 63.84% |
| 2009 | -8.63 | -4.43% |
| 2008 | -9.03 | -59.35% |
| 2007 | -22.2 | -33.76% |
| 2006 | -33.5 | 360.74% |
| 2005 | -7.28 | -13.96% |
| 2004 | -8.46 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -52.59% | 🇺🇸 USA |
 Pfizer PFE | 14.2 | -36.82% | 🇺🇸 USA |
 Eli Lilly LLY | 137 | 513.24% | 🇺🇸 USA |
 Sanofi SNY | 15.0 | -33.04% | 🇫🇷 France |
 Baxter BAX | 8.01 | -64.23% | 🇺🇸 USA |
 MannKind Corp MNKD | -21.9 | -197.76% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.